Search Results for keywords:"Drug Enforcement Administration"

The Department of Justice's Drug Enforcement Administration (DEA) is seeking public comments on its information collection proposal related to electronic prescriptions for controlled substances. This collection is critical for verifying practitioners' identities and managing their access to prescription systems securely. Affected groups include businesses, non-profits, and government entities, required to respond mandatorily. The DEA estimates that the total annual time burden for respondents will be 107,733 hours, with no additional cost burdens. Comments on the proposal will be accepted until March 3, 2025.

The Department of Justice, specifically the Drug Enforcement Administration (DEA), announced a notice for public commentary on its information collection request related to the National Forensics Laboratory Information System. This system gathers drug analysis data from non-federal labs to improve accuracy on drug information. The DEA is seeking approval from the Office of Management and Budget (OMB) for a three-year extension without changes to the existing collection, which involves responses from various agencies and businesses. Public comments on the burden and utility of this data collection are being accepted until March 3, 2025.

The Drug Enforcement Administration (DEA) is proposing a new rule to require that all applications and renewals for DEA registration be submitted online. This change will eliminate the current option to submit paper forms, making the process more efficient and cost-effective. The proposal is expected to save money for both the DEA and applicants by reducing errors and the need for corrections, while nearly all current applicants already use the internet for submissions. The rule change also aligns with federal efforts to streamline and modernize regulatory processes.

The Drug Enforcement Administration (DEA) is proposing to place the substance 4-chloromethcathinone (4-CMC) in schedule I of the Controlled Substances Act. This move aims to impose strict regulations similar to other highly controlled drugs, as 4-CMC is known to have a high potential for abuse and no accepted medical use in the U.S. The decision also helps the United States comply with international agreements on psychotropic substances. Public comments on this proposal are accepted until January 29, 2025.

The Drug Enforcement Administration (DEA), part of the Department of Justice, has released a notice regarding an extension of a previously approved information collection related to the registration of those handling controlled substances. This involves DEA Forms 225, 225a, and 225b for businesses and individuals involved in the manufacturing, distribution, or research of controlled substances. The DEA is seeking public comments on the necessity, accuracy, and potential burden of this information collection process, which is estimated to affect 16,560 registrants and require 3,323 hours annually. Comments are welcome until May 27, 2025.

In January 2025, the Drug Enforcement Administration and the Department of Health and Human Services published new rules about expanding telemedicine practices. These rules were supposed to take effect on February 18, 2025, but have been delayed to March 21, 2025. This delay aligns with a Presidential order for a "Regulatory Freeze Pending Review," allowing more time for feedback on the rules. The rules allow certain medical professionals to prescribe medications via telemedicine, even without an initial in-person visit, under specific conditions. Public comments about this delay are encouraged, focusing on potential policy, legal, and factual issues.

In the Federal Register notice titled "Ibrahim Al-Qawaqneh, D.D.S.; Decision and Order," the DEA sought to revoke Dr. Ibrahim Al-Qawaqneh's registration due to his exclusion from federal health care programs after pleading nolo contendere to a charge of offering unlawful Medi-Cal remuneration. Despite being given a chance to defend himself, the DEA found that Dr. Al-Qawaqneh failed to take full responsibility for his actions, which led to doubts about his trustworthiness. Consequently, his DEA Certificate of Registration was revoked to ensure compliance with laws regulating controlled substances.

The Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) have decided to delay the start date for two rules about using telemedicine to prescribe certain medications to December 31, 2025. These rules include the "Expansion of Buprenorphine Treatment via Telemedicine Encounter," which allows practitioners to prescribe medications for opioid use disorder, and "Continuity of Care via Telemedicine for Veterans Affairs Patients," which permits Veterans Affairs practitioners to prescribe controlled substances via telemedicine under specific conditions. The delay grants additional time to address any questions or issues and follows public feedback, with some comments favoring an immediate start and others requesting a postponement.

The Drug Enforcement Administration (DEA) temporarily placed a substance called brorphine in Schedule I of the Controlled Substances Act due to its high potential for abuse, lack of accepted medical use, and potential danger to public safety. This action means strict regulatory controls are now in place regarding the manufacturing, distribution, and possession of brorphine. The DEA found brorphine on the illicit market in several countries and associated it with several fatalities in the U.S. Brorphine is a synthetic opioid with effects similar to fentanyl, which poses significant health risks and has been linked to the ongoing opioid epidemic. This temporary scheduling will last for two years and can be extended for an additional year.

The Department of Justice's Drug Enforcement Administration (DEA) is seeking public comments on a new information collection proposal. They aim to revise existing forms (DEA Forms 224 and 224A) to include emergency medical services (EMS) agencies under the Controlled Substances Act. This change would allow EMS agencies to register to handle controlled substances in line with state law. The comment period is open for 30 days, during which people can share their thoughts on the proposal's necessity, accuracy, and possible burden on those required to respond.